DE3167757D1 - Dibenz(b,f)(1,4)oxazepine derivatives, process for preparing the same, and pharmaceutical compositions comprising the same - Google Patents

Dibenz(b,f)(1,4)oxazepine derivatives, process for preparing the same, and pharmaceutical compositions comprising the same

Info

Publication number
DE3167757D1
DE3167757D1 DE8181110655T DE3167757T DE3167757D1 DE 3167757 D1 DE3167757 D1 DE 3167757D1 DE 8181110655 T DE8181110655 T DE 8181110655T DE 3167757 T DE3167757 T DE 3167757T DE 3167757 D1 DE3167757 D1 DE 3167757D1
Authority
DE
Germany
Prior art keywords
same
group
dibenz
preparing
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8181110655T
Other languages
English (en)
Inventor
Kiyohiko Ito
Masuo Koizumi
Yasushi Murakami
Mitchitaka Akima
Jinichiro Aono
Yasuhiro Ohba
Tamotsu Yamazaki
Kazushige Sakai
Shun-Ichi Hata
Shigeru Takanashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE3167757D1 publication Critical patent/DE3167757D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE8181110655T 1980-12-24 1981-12-21 Dibenz(b,f)(1,4)oxazepine derivatives, process for preparing the same, and pharmaceutical compositions comprising the same Expired DE3167757D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP55181831A JPS57106673A (en) 1980-12-24 1980-12-24 Dibenzo(b,f)(1,4)oxazepin derivative

Publications (1)

Publication Number Publication Date
DE3167757D1 true DE3167757D1 (en) 1985-01-24

Family

ID=16107575

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8181110655T Expired DE3167757D1 (en) 1980-12-24 1981-12-21 Dibenz(b,f)(1,4)oxazepine derivatives, process for preparing the same, and pharmaceutical compositions comprising the same
DE198181110655T Pending DE54951T1 (de) 1980-12-24 1981-12-21 Dibenzo(b,f)(1,4)oxazepin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE198181110655T Pending DE54951T1 (de) 1980-12-24 1981-12-21 Dibenzo(b,f)(1,4)oxazepin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Country Status (6)

Country Link
US (1) US4379150A (de)
EP (1) EP0054951B1 (de)
JP (1) JPS57106673A (de)
AT (1) ATE10741T1 (de)
CA (1) CA1169059A (de)
DE (2) DE3167757D1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5899471A (ja) * 1981-12-07 1983-06-13 Tanabe Seiyaku Co Ltd ベンゾチアゼピン誘導体の新規製造法
US4940704A (en) * 1989-08-16 1990-07-10 Hoechst-Roussel Pharmaceutical Inc. Pyrido[3,4-b][1,4]benzoxazepines
CA2024040C (en) * 1989-08-29 2002-02-19 Karl D. Hargrave Dibenz [b,f] [1,4]oxazepin (and thiazepin)-11 (10h)-ones and-thiones and their use in the prevention or treatment of aids
GB9021813D0 (en) * 1990-10-08 1990-11-21 Ici Plc Tricyclic heterocycles
US5212169A (en) * 1991-10-31 1993-05-18 G. D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
US5304644A (en) * 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
US5449673A (en) * 1992-08-13 1995-09-12 G. D. Searle & Co. 10,11-dihydro-10-(3-substituted-1-oxo-2-propyl, propenyl or propynyl)dibenz[b,f][1,4] oxazepine prostaglandin antagonists
US5395932A (en) * 1993-04-30 1995-03-07 G. D. Searle & Co. 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5354746A (en) * 1993-06-01 1994-10-11 G. D. Searle & Co. Squaric acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5461047A (en) * 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5354747A (en) * 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5424424A (en) * 1993-10-07 1995-06-13 G. D. Searle & Co. Tartaric acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5488046A (en) * 1993-11-03 1996-01-30 G. D. Searle & Co. Carbamic acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5441950A (en) * 1994-06-09 1995-08-15 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use
US5449675A (en) * 1994-06-09 1995-09-12 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine urea compounds, pharmaceutical compositions and methods of use
US5698551A (en) * 1995-04-07 1997-12-16 Novo Nordisk A/S Heterocyclic compounds
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
DE10242488A1 (de) * 2002-09-13 2004-03-25 Bayer Ag Dibenzoxazeptine
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
KR20130028055A (ko) 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
SG182783A1 (en) 2010-02-09 2012-09-27 Glaxo Group Ltd Treatment of a metabolic disorder
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
PL2580240T4 (pl) 2010-06-14 2020-03-31 Lykera Biomed S.A. Przeciwciała s100a4 i ich terapeutyczne zastosowania
PT2643352T (pt) 2010-11-23 2018-08-01 Glaxo Group Ltd Proteínas de ligação a antigénio para a oncostatina m (osm)
WO2012135415A1 (en) 2011-03-29 2012-10-04 Glaxosmithkline Llc Buffer system for protein purification
US20140023655A1 (en) 2011-04-07 2014-01-23 Glaxosmithkline Llc Formulations with reduced viscosity
LT3415531T (lt) 2011-05-27 2023-09-25 Glaxo Group Limited Bcma (cd269/tnfrsf17) – surišantys baltymai
CN104395343A (zh) 2012-07-05 2015-03-04 葛兰素集团有限公司 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
AU2013295543B2 (en) 2012-07-27 2019-03-14 Aragon Pharmaceuticals, Inc. Methods and compositions for determining resistance to androgen receptor therapy
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
EP2969098B1 (de) 2013-03-15 2019-10-30 Glaxosmithkline Intellectual Property (No. 2) Limited Verfahren zur aufreinigung von antikörpern
RU2015136856A (ru) 2013-03-15 2017-04-21 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Применение промежуточных соединений цикла трикарбоновых кислот (ТСА) для контроля образования аммиака в культуре клеток
AU2014230741B2 (en) 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
US10537638B2 (en) 2013-03-15 2020-01-21 Glaxosmithkline Intellectual Property (No.2) Limited Low concentration antibody formulations
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
US10273311B2 (en) 2014-06-26 2019-04-30 Yale University Compositions to regulate renalase in the treatment of diseases and disorders
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EP3331918A1 (de) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen und verwendungen und verfahren dafür
AU2016303550B2 (en) 2015-08-04 2019-06-13 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP3331917A1 (de) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen sowie verwendungen und verfahren davon
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
CN108136024A (zh) 2015-08-06 2018-06-08 葛兰素史密斯克莱知识产权发展有限公司 Tlr4激动剂及其组合物和它们在治疗癌症中的用途
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
ES2842306T3 (es) 2015-09-02 2021-07-13 Immutep Sas Anticuerpos anti LAG-3
JP2019505476A (ja) 2015-12-01 2019-02-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 組合せ処置およびその方法
EP3494140A1 (de) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos- und anti-pd-1-antikörper-kombinationstherapie
GB201614627D0 (en) 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
SG11201901059QA (en) 2016-09-07 2019-03-28 Glaxosmithkline Ip Dev Ltd Methods for purifying antibodies
BR112019011370A2 (pt) 2016-12-01 2019-10-15 Glaxosmithkline Ip Dev Ltd terapia de combinação
KR20190090823A (ko) 2016-12-01 2019-08-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 요법
WO2018150326A1 (en) 2017-02-15 2018-08-23 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
US20200181275A1 (en) 2017-06-09 2020-06-11 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
EP3634483A1 (de) 2017-06-09 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie
US20200190195A1 (en) 2017-06-09 2020-06-18 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
EP3692066A2 (de) 2017-09-14 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlung von krebs
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
TW202000891A (zh) 2018-03-07 2020-01-01 英商葛蘭素史克智慧財產發展有限公司 純化抗體之方法
TW202003555A (zh) 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
BR112020023451A2 (pt) 2018-05-31 2021-02-23 Glaxosmithkline Intellectual Property Development Limited terapia combinada
JP2021525271A (ja) 2018-05-31 2021-09-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｉｃｏｓ結合タンパク質及びアルギニンメチルトランスフェラーゼ阻害剤を用いた複合療法
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
WO2020030571A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
AU2019366321A1 (en) 2018-10-22 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Dosing
JP2022524921A (ja) 2019-02-01 2022-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド がんを治療するための、ペムブロリズマブと組み合わせたベランタマブマフォドチン
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021046293A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
EP4096718A1 (de) 2020-01-28 2022-12-07 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen und verwendungen und verfahren dafür
GB202004371D0 (en) 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
US20230140694A1 (en) 2020-04-14 2023-05-04 GlaxoSmithKline Intellectual Property Developement Limited Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
US20230149543A1 (en) 2020-04-14 2023-05-18 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
AU2021257570A1 (en) 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
WO2022117526A1 (en) 2020-12-02 2022-06-09 Glaxosmithkline Intellectual Property Development Limited Il-7 binding proteins and their use in medical therapy
EP4308605A1 (de) 2021-03-19 2024-01-24 GlaxoSmithKline Intellectual Property Development Limited Gegen claudin-3 gerichtete chimäre antigenrezeptoren und verfahren zur behandlung von krebs
WO2023041985A2 (en) 2021-09-15 2023-03-23 New York University In Abu Dhabicorporation Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
WO2023227641A1 (en) 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment
WO2024097796A1 (en) 2022-11-02 2024-05-10 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
WO2024097441A1 (en) 2022-11-02 2024-05-10 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH420155A (de) * 1963-01-03 1966-09-15 Wander Ag Dr A Verfahren zur Herstellung von in 10-Stellung basisch substituierten Dibenz(b,f)(1,4)oxazepinon-Derivaten
CH484931A (de) * 1965-06-23 1970-01-31 Ciba Geigy Verfahren zur Herstellung von Oxazaheterocyclen
FR4500M (de) * 1965-07-15 1966-10-10
DE1670414A1 (de) * 1966-12-17 1970-10-29 Ciba Geigy Oxyzaheterocyclen

Also Published As

Publication number Publication date
DE54951T1 (de) 1983-04-28
EP0054951A1 (de) 1982-06-30
EP0054951B1 (de) 1984-12-12
JPS57106673A (en) 1982-07-02
US4379150A (en) 1983-04-05
CA1169059A (en) 1984-06-12
ATE10741T1 (de) 1984-12-15

Similar Documents

Publication Publication Date Title
DE3167757D1 (en) Dibenz(b,f)(1,4)oxazepine derivatives, process for preparing the same, and pharmaceutical compositions comprising the same
ES8609247A1 (es) Un procedimiento para la preparacion de derivados del indol
HUT38210A (en) Insecticidal, miticidal and nematocidal compositions comprising nitromethylene derivatives as active substance and process for producing the active substances
ATE185807T1 (de) Thiazolylbenzofuranderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die sie enthalten
NO164351C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-alkyl-l-fenyl-2-piperazinoalkylpyrazolin-3-on-forbindelser.
IE822310L (en) Triazoloquinazolone derivatives
ZA815043B (en) Diazepine derivatives,process for their preparation,and pharmaceutical compositions thereof
IL69734A (en) 1-phenyl-1-aminomethyl cyclobutane derivatives,process for their preparation and pharmaceutical compositions containing them
IL61687A (en) (benzothiazole-2-yl-thio)-phenylpropionic acid derivatives,pharmaceutical formulations containing them and a process for their preparation
ZA876625B (en) Benzhydryloxyethylpiperidine derivatives,process for their preparation and pharmaceutical compositions in which they are present
ATE123487T1 (de) Derivate der kaffeinsäure und sie enthaltende pharmazeutische zusammensetzungen.
DE3474145D1 (en) Benzothiazolone derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
NO914577L (no) Fremgangsmaate for fremstilling av heterocyklisk substituerte piperazinoalkylbenzoksazin- og -tiazinforbindelser
DE3365933D1 (en) Substituted thienobenzodiazepinones, process for their preparation and medicines containing these compounds
ES8405020A1 (es) Un procedimiento para la preparacion de derivados de fosfolipidos.
FI851456A0 (fi) Foerfarande foer framstaellning av 1-cyklohexyl-3,4-dihydroisokinolinderivat.
HUT44502A (en) Process for producing 3-amino-dihydropyridine derivatives and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee